Comparison Between Carbapenems and Noncarbapenem Beta-lactam Antibiotics in Septic Burn Patients

Launched by AIN SHAMS UNIVERSITY · Jul 24, 2025

Keywords

ClinConnect Summary

This clinical trial is studying how well two types of antibiotics work as the first treatment for sepsis in patients with burns. Sepsis is a serious infection that can happen after a burn injury. The trial will compare Meropenem, a strong antibiotic called a carbapenem, with Piperacillin/Tazobactam, another type of antibiotic that is not a carbapenem, to see which one is more effective in treating these infections.

People who might be eligible to join this study are adults between 21 and 60 years old who have burns and develop sepsis while being treated at the Burn Unit of Ain Shams University Hospitals. To take part, patients must not have been transferred from other hospitals and should be in relatively good health before the burn (classified as ASA I or II). Participants can expect to receive one of the two antibiotics as their first treatment for sepsis. It’s important to know that this study has not started recruiting yet, and patients who refuse to participate, who do not have sepsis, or who pass away within 24 hours of admission will not be included. This trial hopes to help doctors choose the best antibiotic to improve care for burn patients with serious infections.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Burned patients admitted to Burn Unit of Ain Shams university hospitals diagnosed with sepsis, not transferred from other hospitals, Age group between 21 - 60 years old, ASA I and II.
• Exclusion Criteria:
• • Refusal of participation in the study,
• • Patient with no signs of sepsis,
• • Patients who died within 24 hours after admission,
• • Patients concomitantly received carbapenems and other broad-spectrum beta-lactams,
• • Data from the second and subsequent hospitalizations of patients who were hospitalized multiple times during the study period and used only the data from the first hospitalization,
• • Patients younger than 21 years old and older than 60 years old.